Large pharmaceutical companies against the EU: Who should pay urban wastewater?
Drugs and cosmetic actors have sought European courts to compete with at least 80% of the treatment designed to remove microfolists from urban wastewater.
Actors of the pharmaceutical and cosmetics industry appealed to the European Union’s court to oppose the order of urban wastewater.
According to the European directive, which came into effect on January 1, 2025, according to the pollution principle that at least 80% of the treatment of medicines and cosmetics manufacturers should be financed to remove microflone from urban wastewater.
Water Europe’s President Hans Gusons told EuroNus that more than 90% of the “microfoldings emerging from the wastewater treatment plants are from medicine and cosmetics.”
Therefore, “80%of these waste elimination costs are” accepted by the creators “as” reasonable “.
“The pollution of the pollution is the source of the European Environmental Policy,” he added.
Fees
On the other hand, the drugs and cosmetic fields are considered that the fees should be divided in a very uniform manner.
“We are all in favor of paying our pollution quota we are creating, but it must be a reasonable quota,” director of European Industries and Pharmaceutical Societies (EFPIA) told Nathali Mol Euronevs.
“We are trying to find out who different pollutants are and we ensure that this important order has been established based on the right principles, and all the interventions are involved. Not only will they pay their reservation, but also ensure that they are encouraged to produce more stable products in the future.”
The director of EFPIA regrets that the European Commission’s instructions and data are not approached.
A heavy invoice
The European Commission estimates the price of additional treatment at waste water treatment plants at 1.2 billion euros per year.
Although this is a trivialist compared to the business size of the pharmaceutical industry, the drug for Europe considers that this order is “unprecedented” and the risk of access and access to drug prices.
“Since we cannot legally increase the price of drugs in Europe, it will not get these drugs for patients and a shortage of tsunami,” Medical Director General of Europea Van Den Howan told EuroNius.
For example, the price of diabetes is likely to increase by 900% and an antibiotic amoxicillin may increase by 350%, the director says.
Overall, the contract intervene in the pharmaceutical and cosmetics industry, including Healthcare France, dermaparum, epia, admatical pharma, hexel and cosmetic Europe, 16 actions in the EU’s court.
Poland recommended the case in the EU court.
AdvertisementThe Commission’s response
The Commission, which is in contact with the Euronevas, confirms that the potential effects of the manufacturer’s expanded responsibility for the manufacturer in the pharmaceutical industry have been carefully evaluated in the assessment.
The commission spokesman said that “the effects of the pharmaceutical products and the” reduction in industrial profits are somewhat. “
This directive provides significant flexibility in calculating rates for member states and ensures that they are proportional and do not affect the access and prices of drugs, ”he said.
